Cytosorbents (CTSO) Revenue Growth (5y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Cytosorbents | 28.81 Mn | 24.01 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.51% |
| Dec 31, 2025 | -5.04% |
| Sep 30, 2025 | -2.10% |
| Jun 30, 2025 | -0.37% |
| Mar 31, 2025 | 0.05% |
| Dec 31, 2024 | 4.25% |
| Sep 30, 2024 | 7.16% |
| Jun 30, 2024 | 7.25% |
| Mar 31, 2024 | 11.61% |
| Dec 31, 2023 | 7.35% |
| Sep 30, 2023 | 8.94% |
| Jun 30, 2023 | 10.36% |
| Mar 31, 2023 | 13.92% |
| Dec 31, 2022 | 15.11% |
| Sep 30, 2022 | 16.23% |
| Jun 30, 2022 | 18.96% |
| Mar 31, 2022 | 22.79% |
| Dec 31, 2021 | 28.45% |
| Sep 30, 2021 | 32.26% |
| Jun 30, 2021 | 40.17% |
| Mar 31, 2021 | 42.40% |
| Dec 31, 2020 | 46.68% |
| Sep 30, 2020 | 51.00% |
| Jun 30, 2020 | 59.00% |
| Mar 31, 2020 | 64.49% |
| Dec 31, 2019 | 53.44% |
| Sep 30, 2019 | 39.29% |
| Jun 30, 2019 | 43.49% |
| Mar 31, 2019 | 37.35% |
| Dec 31, 2018 | 26.00% |
| Sep 30, 2018 | 53.35% |
| Jun 30, 2018 | 114.09% |
| Mar 31, 2018 | 94.68% |
| Dec 31, 2017 | 121.09% |
| Sep 30, 2017 | 208.53% |
| Jun 30, 2017 | 134.77% |
| Mar 31, 2017 | 128.28% |
| Dec 31, 2016 | 143.42% |